UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Journal of hematology and oncology, 2018-01, Vol.11 (1), p.15-15, Article 15

2018

Volltextzugriff (PDF)

Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma

Nature communications, 2019-09, Vol.10 (1), p.4209-14, Article 4209

2019

Volltextzugriff (PDF)

Recurrent PDGFRB mutations in unicentric Castleman disease

Leukemia, 2019-04, Vol.33 (4), p.1035-1038

2019

Volltextzugriff (PDF)

NALCN is a potential biomarker and therapeutic target in human cancers

Frontiers in genetics, 2023-04, Vol.14, p.1164707-1164707

2023

Volltextzugriff (PDF)

Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma

Frontiers in endocrinology (Lausanne), 2022-04, Vol.13, p.846357-846357

2022

Volltextzugriff (PDF)

Folate receptor-positive circulating tumor cell count, lymphocyte count and derived neutrophil-to- lymphocyte ratio for diagnosing lung cancer relapse

Frontiers in oncology, 2023-01, Vol.12, p.1097816-1097816

2023

Volltextzugriff (PDF)

Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience

Frontiers in immunology, 2022-08, Vol.13, p.929221-929221

2022

Volltextzugriff (PDF)

First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3026-3026

2020

Volltextzugriff (PDF)

AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma

Molecular medicine (Cambridge, Mass.), 2018-07, Vol.24 (1), p.35-35, Article 35

2018

Volltextzugriff (PDF)

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma

Cancer medicine (Malden, MA), 2023-04, Vol.12 (7), p.8134-8143

2023

Volltextzugriff (PDF)

Genomic and outcome analysis of adult T-cell lymphoblastic lymphoma

Haematologica (Roma), 2020-03, Vol.105 (3), p.e107-e110

2020

Volltextzugriff (PDF)

Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients

Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920923829

2020

Volltextzugriff (PDF)

Expression of AEG-1 in human T-cell lymphoma enhances the risk of progression

Oncology reports, 2012-12, Vol.28 (6), p.2107-2114

2012

Volltextzugriff (PDF)

Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study

Indian journal of hematology & blood transfusion, 2022-01, Vol.38 (1), p.42-50

2022

Volltextzugriff (PDF)

Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?

Cancer cell international, 2018-10, Vol.18 (1), p.150-150, Article 150

2018

Volltextzugriff (PDF)

Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma

Leukemia & lymphoma, 2015-01, Vol.56 (9), p.2613-2618

2015

Volltextzugriff (PDF)

Follicular dendritic cell sarcoma of the pharyngeal region

Oncology letters, 2013-05, Vol.5 (5), p.1467-1476

2013

Volltextzugriff (PDF)

Autologous nanobody-derived fratricide-resistant CD7-CAR T cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma

Clinical cancer research, 2022-07, Vol.28 (13), p.2830-2843

2022

Volltextzugriff (PDF)

A Phase I/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)

Blood, 2022-11, Vol.140 (Supplement 1), p.12075-12076

2022

Volltextzugriff (PDF)

MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1

Cancer biology & therapy, 2019-01, Vol.20 (1), p.31-41

2019

Volltextzugriff (PDF)

Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T‐cell lymphoma: A randomized, controlled, open‐label, multicenter study

International journal of cancer, 2021-03, Vol.148 (6), p.1470-1477

2021

Volltextzugriff (PDF)

Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial

Blood, 2021-11, Vol.138 (Supplement 1), p.1368-1368

2021

Volltextzugriff (PDF)

The relationship and clinical significance of serum cytokine expression level and skin pruritus in patients with Hodgkin lymphoma and angioimmunoblastic T-cell lymphoma

International immunopharmacology, 2024-04, Vol.131, p.111777-111777, Article 111777

2024

Volltextzugriff (PDF)

Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial

Journal of neuro-oncology, 2018-11, Vol.140 (2), p.427-434

2018

Volltextzugriff (PDF)

Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma

Leukemia & lymphoma, 2023-02, Vol.64 (3), p.605-612

2023

Volltextzugriff (PDF)

1 – 25 von 247

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(226)
Mit Volltextzugriff
(223)

Publikationsform

Sprache

Englisch
(238)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(172)
Life Sciences & Biomedicine
(86)
Physical Sciences
(74)
Chemistry
(55)
Technology
(52)
Humans
(35)
Materials Science
(33)
Oncology
(28)
Chemistry, Multidisciplinary
(27)
Materials Science, Multidisciplinary
(27)
Chemistry, Physical
(24)
Physics
(23)
Electrochemistry
(21)
Science & Technology - Other Topics
(20)
Lymphoma
(19)
Chemotherapy
(17)
Physics, Applied
(17)
Animals
(15)
Female
(15)
Male
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma

Recurrent PDGFRB mutations in unicentric Castleman disease

NALCN is a potential biomarker and therapeutic target in human cancers

Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma

Folate receptor-positive circulating tumor cell count, lymphocyte count and derived neutrophil-to- lymphocyte ratio for diagnosing lung cancer relapse

Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience

First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma

AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma

Genomic and outcome analysis of adult T-cell lymphoblastic lymphoma

Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients

Expression of AEG-1 in human T-cell lymphoma enhances the risk of progression

Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study

Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?

Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma

Follicular dendritic cell sarcoma of the pharyngeal region

Autologous nanobody-derived fratricide-resistant CD7-CAR T cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma

A Phase I/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)

MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1

Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T‐cell lymphoma: A randomized, controlled, open‐label, multicenter study

Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial

The relationship and clinical significance of serum cytokine expression level and skin pruritus in patients with Hodgkin lymphoma and angioimmunoblastic T-cell lymphoma

Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial

Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma

Suchergebnisse filtern